{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T09:27:03Z","timestamp":1792661223025,"version":"4.5.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicon"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.toxicon.2015.09.037","type":"journal-article","created":{"date-parts":[[2015,10,14]],"date-time":"2015-10-14T10:07:29Z","timestamp":1444817249000},"page":"72-76","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"PA","title":["Is it time for flexibility in botulinum inter-injection intervals?"],"prefix":"10.1016","volume":"107","author":[{"given":"Oluwadamilola O.","family":"Ojo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert H.","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.toxicon.2015.09.037_bib1","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/j.1468-1331.2006.01537.x","article-title":"A\u00a0systematic review on the diagnosis and treatment of primary (idiopathic) dystonia and dystonia plus syndromes: report of an EFNS\/MDS-ES task force","volume":"13","author":"Albanese","year":"2006","journal-title":"Eur. J. Neurol."},{"issue":"1","key":"10.1016\/j.toxicon.2015.09.037_bib2","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1468-1331.2010.03042.x","article-title":"EFNS guidelines on diagnosis and treatment of primary dystonias","volume":"18","author":"Albanese","year":"2011","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.toxicon.2015.09.037_bib3","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1016\/S0041-0101(01)00101-5","article-title":"A\u00a0comparison of the safety margins of botulinum neurotoxin serotypes A, B, and F in mice","volume":"39","author":"Aoki","year":"2001","journal-title":"Toxicon"},{"issue":"23","key":"10.1016\/j.toxicon.2015.09.037_bib4","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1080\/01421590701568262","article-title":"Botulinum toxin treatment of axial and cervical dystonia","volume":"29","author":"Benecke","year":"2007","journal-title":"Disabil. Rehabil."},{"issue":"9","key":"10.1016\/j.toxicon.2015.09.037_bib5","doi-asserted-by":"crossref","first-page":"618","DOI":"10.3111\/13696998.2014.925462","article-title":"Satisfaction with botulinum toxin treatment in poststroke spasticity: results from two cross-sectional surveys (patients and physicians)","volume":"17","author":"Bensmail","year":"2014","journal-title":"J.\u00a0Med. Econ."},{"key":"10.1016\/j.toxicon.2015.09.037_bib6","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1212\/WNL.46.1.26","article-title":"Botulinum toxin therapy, immunologic resistance and problems with available materials","volume":"46","author":"Borodic","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.toxicon.2015.09.037_bib8","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1016\/S0149-2918(00)83049-0","article-title":"Duration of effect of botulinum toxin type A in adult patients with cervical dystonia: a retrospective chart review","volume":"22","author":"Brashear","year":"2000","journal-title":"Clin. Ther."},{"issue":"10","key":"10.1016\/j.toxicon.2015.09.037_bib9","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/mds.22157","article-title":"CD-017 BoNTA Study Group. Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay","volume":"23","author":"Brin","year":"2008","journal-title":"Mov Disord"},{"key":"10.1016\/j.toxicon.2015.09.037_bib10","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1128\/IAI.66.6.2420-2425.1998","article-title":"Biophysical characterization of the stability of the 150-kilodalton botulinum toxin, the nontoxic component, and the 900-kilodalton botulinum toxin complex species","volume":"66","author":"Chen","year":"1998","journal-title":"Infect. Immun."},{"issue":"394","key":"10.1016\/j.toxicon.2015.09.037_bib11","first-page":"A82","article-title":"Botulinum toxin A antibodies in initial and delayed resistance to Botulinum toxin A therapy in cervical dystonia","volume":"10","author":"Duane","year":"1995","journal-title":"Mov. Disord."},{"issue":"9","key":"10.1016\/j.toxicon.2015.09.037_bib12","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1136\/jnnp-2012-303608","article-title":"Long-term efficacy and safety of incobotulinumtoxinA injections in patients with cervical dystonia","volume":"84","author":"Dressler","year":"2013","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.toxicon.2015.09.037_bib13","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s00702-013-1076-z","article-title":"Botulinum toxin therapy of cervical dystonia: comparing onabotulinumtoxinA (Botox\u00ae) and incobotulinumtoxinA (Xeomin\u00ae)","volume":"121","author":"Dressler","year":"2014","journal-title":"J.\u00a0Neural Transm."},{"key":"10.1016\/j.toxicon.2015.09.037_bib14","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.toxicon.2008.04.030","article-title":"Dissociation of the 900 kDa neurotoxin complex from C. botulinum under physiological conditions","volume":"51","author":"Eisele","year":"2008","journal-title":"Toxicon"},{"issue":"12","key":"10.1016\/j.toxicon.2015.09.037_bib15","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1007\/s00702-013-1048-3","article-title":"A\u00a0randomized double blind study of repeated incobotulinumtoxinA (Xeomin\u00ae) in cervical dystonia","volume":"120","author":"Evidente","year":"2013","journal-title":"J.\u00a0Neural Tansm"},{"issue":"4","key":"10.1016\/j.toxicon.2015.09.037_bib16","doi-asserted-by":"crossref","first-page":"273","DOI":"10.5334\/tohm.185","article-title":"Botulinum toxin therapy for cervical dystonia: the science of dosing","volume":"12","author":"Evidente","year":"2014","journal-title":"Tremor Other Hyperkinet Mov. (NY)"},{"issue":"1\u20132","key":"10.1016\/j.toxicon.2015.09.037_bib17","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jns.2014.08.004","article-title":"IncobotulinumtoxinA (Xeomin\u00ae) injected for blepharospasm or cervical dystonia according to patient needs is well tolerated","volume":"346","author":"Evidente","year":"2014","journal-title":"J.\u00a0Neurol. Sci."},{"issue":"2","key":"10.1016\/j.toxicon.2015.09.037_bib18","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/mds.870090216","article-title":"Development of resistance to botulinum toxin type A in patients with torticollis","volume":"9","author":"Greene","year":"1994","journal-title":"Mov. Disord."},{"key":"10.1016\/j.toxicon.2015.09.037_bib20","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1212\/WNL.45.9.1743","article-title":"Response and immunoresistance to botulinum toxin injections","volume":"45","author":"Jankovic","year":"1995","journal-title":"Neurology"},{"key":"10.1016\/j.toxicon.2015.09.037_bib21","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1212\/01.WNL.0000055087.96356.BB","article-title":"Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia","volume":"60","author":"Jankovic","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.toxicon.2015.09.037_bib22","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/mds.23658","article-title":"Efficacy and safety of incobotulinumtoxinA (NT 201, Xeomin) in the treatment of blepharospasm\u2014a randomized trial","volume":"26","author":"Jankovic","year":"2011","journal-title":"Mov. Disord."},{"issue":"4","key":"10.1016\/j.toxicon.2015.09.037_bib23","first-page":"265","article-title":"Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency. German Dystonia Study Group","volume":"246","author":"Kessler","year":"1999","journal-title":"J.\u00a0Neurol."},{"key":"10.1016\/j.toxicon.2015.09.037_bib24","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/WNF.0b013e3181914d0a","article-title":"Neutralizing antibodies and secondary therapy failure after treatment with botulinum toxin type A: much ado about nothing?","volume":"32","author":"Lange","year":"2009","journal-title":"Clin. Neuropharmacol."},{"issue":"13","key":"10.1016\/j.toxicon.2015.09.037_bib25","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1002\/mds.23254","article-title":"Meta-analysis of neutralizing antibody conversion with onabotulinumtoxinA (BOTOX(R)) across multiple indications","volume":"25","author":"Naumann","year":"2010","journal-title":"Mov. Disord."},{"key":"10.1016\/j.toxicon.2015.09.037_bib26","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1128\/IAI.16.1.107-109.1977","article-title":"Oral toxicities of Clostridium botulinum toxins in response to molecular size","volume":"16","author":"Ohishi","year":"1977","journal-title":"Infect. Immun."},{"key":"10.1016\/j.toxicon.2015.09.037_bib27","doi-asserted-by":"crossref","first-page":"419","DOI":"10.3111\/13696998.2011.653726","article-title":"Satisfaction with botulinum toxin treatment: a cross-sectional survey of patients with cervical dystonia","volume":"15","author":"Sethi","year":"2012","journal-title":"J.\u00a0Med. Econ."},{"issue":"19","key":"10.1016\/j.toxicon.2015.09.037_bib28","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1212\/01.wnl.0000311389.26145.95","article-title":"Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based. review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology","volume":"70","author":"Simpson","year":"2008","journal-title":"Neurology"},{"issue":"Suppl.\u00a07","key":"10.1016\/j.toxicon.2015.09.037_bib29","first-page":"A316","article-title":"Neutralizing antibody formation is rare following repeated injections of a low-protein formulation of botulinum toxin type A (BTX-A) in patients with post-stroke spasticity","volume":"58","author":"Turkel","year":"2002","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.toxicon.2015.09.037_bib30","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1007\/s00702-013-0998-9","article-title":"Xeomin US Blepharospasm Study Group. Sustained efficacy and safety of repeated incobotulinumtoxinA (Xeomin(\u00ae)) injections in blepharospasm","volume":"120","author":"Truong","year":"2013","journal-title":"J.\u00a0Neural Transm."},{"key":"10.1016\/j.toxicon.2015.09.037_bib31","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1212\/WNL.43.9.1715","article-title":"Botulinum antibodies in dystonic patients treated with type A botulinum toxin: frequency and significance","volume":"43","author":"Zuber","year":"1993","journal-title":"Neurology"}],"container-title":["Toxicon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041010115301033?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041010115301033?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,9]],"date-time":"2020-09-09T19:15:02Z","timestamp":1599678902000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041010115301033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":29,"alternative-id":["S0041010115301033"],"URL":"https:\/\/doi.org\/10.1016\/j.toxicon.2015.09.037","relation":{},"ISSN":["0041-0101"],"issn-type":[{"value":"0041-0101","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Is it time for flexibility in botulinum inter-injection intervals?","name":"articletitle","label":"Article Title"},{"value":"Toxicon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.toxicon.2015.09.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}